Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Immune Therapies for Myeloma, With Drs. Saad Usmani and Nikhil Munshi

Immune Therapies for Myeloma, With Drs. Saad Usmani and Nikhil Munshi

FromThe Hematologist


Immune Therapies for Myeloma, With Drs. Saad Usmani and Nikhil Munshi

FromThe Hematologist

ratings:
Length:
21 minutes
Released:
Jul 1, 2021
Format:
Podcast episode

Description

In this podcast, Contributing Editor Dr. Saad Usmani has a conversation with Dr. Nikhil Munshi. They discuss Dr. Usmani’s Mini Review article from the July/August 2021 issue of The Hematologist, titled, "Immune Therapies for Myeloma: The CARs Are Here but What’s Next?" They discuss the latest approvals of chimeric antigen receptor T-cell therapies to treat multiple myeloma. You can access her Mini Review article online at https://ashpublications.org/thehematologist/article/doi/10.1182/hem.V18.4.2021413/476193/Immune-Therapies-for-Myeloma-The-CARs-Are-Here-but?utm_source=sfmc&utm_medium=email&utm_campaign=TheHem+July+2021&utm_term=Link+Text+%c2%bb&utm_id=102625&sfmc_id=32555314.
Additional ASH affiliation and COI information: Dr. Usmani has received research funding from Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, and Takeda; consulting fees from Amgen, BMS, Celgene, EdoPharma, GSK, Janssen, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, and TeneoBio; speaker fees from Amgen, BMS, Janssen, and Sanofi.
Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/
Released:
Jul 1, 2021
Format:
Podcast episode

Titles in the series (100)

The Hematologist is the member newsletter of American Society of Hematology (ASH). It is designed for the broad constituency of ASH, all working toward the ultimate goal of conquering blood diseases. The Hematologist updates readers about important developments in the field of hematology and highlights what ASH is doing for its members.